Incretin mimetics are ideal candidate therapies for T2D as they exert their actions specifically during hyperglycaemic conditions and have the additional capacity to regulate body weight ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
Thyroid disorders can affect sexual function, though this connection is indirect and thyroid dysfunction would typically present with multiple other symptoms
While obesity itself is a known risk factor for certain cancers, the anti-inflammatory effects of GLP-1s will likely prove to have a role in cancer prevention, McDonald said
It was the wrong call, no two ways around it
doi: 10.2174/1570161114666161221115324 43 ScheenAJ